Eli Lilly and Co. (LLY) announced that the European Commission has approved marketing authorization for Kisunla (donanemab). This new treatment is indicated for adults in the early symptomatic stages of Alzheimer's disease—including those with mild cognitive impairment or mild dementia—who have confirmed amyloid pathology and are either ApoE4 heterozygotes or non-carriers.
The Kisunla marketing authorization in the European Union is based on the TRAILBLAZER-ALZ 2 and the TRAILBLAZER-ALZ 6 clinical trials. The Phase 3 TRAILBLAZER-ALZ 2 study demonstrated Kisunla significantly slowed cognitive and functional decline. Cognitive and functional decline involves greater memory and thinking problems, affecting daily activities and needing more caregiver support.
Donanemab, a monthly infusion, is currently marketed as Kisunla in the United States and other countries, including Japan, China, United Kingdom, UAE, Qatar, Kuwait, Bahrain, Singapore, Taiwan, Brazil, Mexico and Australia. In the United States, Japan, China and many other countries, donanemab is approved for patients regardless of ApoE4 status. In the European Union, Kisunla is approved for patients who are ApoE4 heterozygotes or non-carriers.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.